Priority review + drug price negotiation! A new era of lung cancer treatment in China

The way of priority review has opened a green channel for these latest treatment schemes to enter the Chinese market Their coming implementation and application in China will bring good news to Chinese patients But worries about pricing test the affordability of drugs On June 15, the State Drug Administration announced that it approved the marketing of nafulizumab injection (trade name "odivo", opdivo) developed by BMS At present, five immunosuppressant (PD-1 / PD-L1) drugs have been listed in the world, which are the products of BMS, MSD, Roche, AstraZeneca, Merck, Pfizer and other pharmaceutical giants These products have carried out a number of clinical trials in China At present, there are more than 20 domestic drug companies that have approved the clinical trials of PD-1 / PD-L1 monoclonal antibody project, four of which have entered the procedures of listing for approval cription-url="http://mmbiz.qpic.cn/mmbiz_jpg/bASSOTgOKeIIvkXTWFjOIENXo9mPVSm2PiciaJvDxm1kopMneAnjUXs0CwN57tubamosRDR4luICqI7IVJNToLkw/0?wx_fmt=jpeg" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/bASSOTgOKeIIvkXTWFjOIENXo9mPVSm2PiciaJvDxm1kopMneAnjUXs0CwN57tubamosRDR4luICqI7IVJNToLkw/640?wx_fmt=jpeg" _width="100%" src="http://www.xinyaohui.com/skin/2016/image/lazy.gif" class="lazy" original="http://www.xinyaohui.com/file/upload/201806/19/153455292002.jpg" data-fail="0" style="margin: 0px; padding: 0px; max-width: 100%; height: auto !im portant; box-sizing: border-box !im portant; word-wrap: break-word !im portant; visibility: visible !im portant; "Width =" 700 "ALT =" wechat picture "height =" 525 "/ > there is no doubt that PD-1 and PD-L1 are the most dazzling" anticancer drugs "in the field of tumor treatment in recent years With the approval of the first PD-1 drug in China, cancer immunotherapy in China is entering a new era cription-url="http://mmbiz.qpic.cn/mmbiz_jpg/bASSOTgOKeIIvkXTWFjOIENXo9mPVSm2CxbmHggPWIlJP0k4cdSQB8IHuWXk68ibows5QZIhRo77ZwRwCM4jqOg/0?wx_fmt=jpeg" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/bASSOTgOKeIIvkXTWFjOIENXo9mPVSm2CxbmHggPWIlJP0k4cdSQB8IHuWXk68ibows5QZIhRo77ZwRwCM4jqOg/640?wx_fmt=jpeg" _width="100%" src="http://www.xinyaohui.com/skin/2016/image/lazy.gif" class="lazy" original="http://www.xinyaohui.com/file/upload/201806/19/153505622002.jpg" data-fail="0" style="margin: 0px; padding: 0px; max-width: 100%; height: auto !im portant; box-sizing: border-box !im portant; word-wrap: break-word !im portant; visibility: visible !im portant; "ALT =" wechat picture "/ > not long ago, at the 54th annual meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, immunotherapy for PD-1 / PD-L1 drugs has been the focus of continuous hot discussion in recent years, and many giants have released the latest data cription-url="http://mmbiz.qpic.cn/mmbiz_jpg/bASSOTgOKeIIvkXTWFjOIENXo9mPVSm2449WSuLGUjIhjoTDw7Pk2nyBDIH688ovCzw3UO9Nb7ZHfgtXMUUyDw/0?wx_fmt=jpeg" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/bASSOTgOKeIIvkXTWFjOIENXo9mPVSm2449WSuLGUjIhjoTDw7Pk2nyBDIH688ovCzw3UO9Nb7ZHfgtXMUUyDw/640?wx_fmt=jpeg" _width="100%" class="img_loading" src="http://www.xinyaohui.com/skin/2016/image/lazy.gif" class="lazy" original="http://www.xinyaohui.com/file/upload/201806/19/153515562002.jpg" style="margin: 0px; padding: 0px; max-width: 100%; border: 1px solid rgb(238, 237, 235); background-image: url("da ta:image/gif;ba se64, R0lGODlhPAA8APYAAJeXl56enp+fn6CgoKGhoaKioqOjo6SkpKWlpaampqenp6ioqKmpqaqqqqurq6ysrK2tra6urq+vr7CwsLGxsbKysrOzs7S0tLW1tba2tre3t7i4uLm5ubq6uru7u7y8vL29vb6+vr+/v8DAwMHBwcLCwsPDw8TExMXFxcbGxsfHx8jIyMnJycrKysvLy8zMzM3Nzc7Ozs/Pz9DQ0NHR0dLS0tPT09TU1NXV1dbW1tfX19nZ2dra2tvb29zc3N3d3eDg4OHh4ePj4wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAkEAEIAIf8LTkVUU0NBUEUyLjADAQAAACwAAAAAPAA8AAAH/oBCgoOEhYaHiImKi4yNjo+QkZKTlJWWl5iZmpuKJgwMJ5ycBQAABaKbBKUEqI9BQUCIA6UDhyELDRytg7BAQYezALWGCgEBDLuCvUCxhcHDhA4CAgELyU LLzYTPhSAF0wMS10LMzL/btIUNAdPW49nngtyDFQPTBBjjyuXaQqoArAYlmCYggr5B/OIZKGVgUAR7Ak5x+tGjh49Dy+JdMGDgwiAG7Aoe8iBBwgdJPXio7PHDUK94hx5MU2CIQ4QEBw5MQKmyZw9DzBghOGDIggIESA+I49lT5cVLFhYgndpABCUfTVdagpBg6oEFFDClbPpzkoOpCBJMIKHJx1ge/mUlPRiK4IEGVG6fUpowocPBv4ADCz7EIweOw4gR88BUIoOFx5AfY0jBKIeNy5gz58B0wcGDz6A/O8hQObNpGzg4ew4N2sHdRTwSy8axAxMJDJEjX2gxuLfv35xu0KB hyYOHEqhsyIDBXAYlDRUoVNAwQpMOGsyzO58EvYJ3Cx1WXKIRIzvzGZY2WPDuHcPJSTmWm49RAxMIDOy9Z6Acacb8+oW0wNsiIljVzQX5+RUJdufdYAgLKaTwgiIjcMBBCIaUwMF6FCgICQ4z0JCaIS9EmIILg7xwwgkTCiKChRwgZ8gJHXAQCicrmNiiECgUiMIgGlroAWAlRsgCISYUe2gCISDAuKQ+MqgQoQoxIKkkISjUyEEHKujTgokoWinCk4NUaKGBycAgZQoq2FBIkmMW8oIHFnZAZitfRhimmHcKQgKMaOJp5CFw9ilICBtsECgqNLjQgpuGFHrICyKMcKRvkgKX yAkF3qjpITRESNynpJZq6qmopopKIAAh+QQJBABFACwAAAAAPAA8AIaVlZWbm5ucnJydnZ2enp6fn5+goKChoaGioqKjo6OkpKSlpaWmpqanp6eoqKipqamqqqqrq6usrKytra2urq6vr6+wsLCxsbGysrKzs7O0tLS1tbW2tra3t7e4uLi5ubm6urq7u7u8vLy9vb2+vr6/v7/AwMDBwcHCwsLDw8PExMTFxcXGxsbHx8fIyMjJycnKysrLy8vMzMzNzc3Ozs7Pz8/Q0NDR0dHS0tLT09PU1NTV1dXX19fY2NjZ2dna2trb29vc3Nzd3d3e3t7f398AAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH/oBFgoOEhYaHiImKi4yNjo+QkZKTlJWWl5iZmpuKKA4OKZycBwAAB6KbBaUFqI9EQ0NEhwSlBIchCw4drYNDQkJDs7WHCgEBDbyCvr/BhbQAtoUPAtQMyUXLv7KEz9GDIg XUBBPX2L/AzsOEDgHV5UVE50Lbgt2EFgPUBRrv5syEqgCwGpSAmgAJ/QTJa1aElKlBEvIJMCAKiA8fQA5lY4jhwAEMgxq0O3hrgoQQknzwWInR0DKGh6YJUGCogwQFCRBQSLmy5w9DvxjlNHRhQYKjCMhFCtKj58oePy9dYHC0qgMSlFQ65dHDUgScVRlUuBREa8+ukyBUTaCAgglN/j+aPqWkFkECCBtQWfRhqUIFDwkDCx5MWJCPHDgSK06cA62lExowXJhM+UKGFYxy2NjMuXMOTBgeQBhNevQDfot0dF5t4/Ol0KVLP8i76AfixYt5YDKRQXLlyRhcFB5OvDgmHDRoWAI B4gSqGzJgSJdBicMFCxc4lNC0g0YM6dOrV8bwQbgl7+Clz7DU4XcGlJN0RE8fowamERp+b2AhiQZ9+4W88AIjI4xgiAgZVPZBf+DNgIMhLaigAgyKlNBBByIYcoIHklkAgiQ5zECDa4XEIKEKAwoSwwknxDAICRd24JwhKXzgQSicsHCii4KgIIIIKAyy4YULJmSihC0QgHLCjzMKIkKMb70zwwoSrkDdICb8GKUgKXhAJH/luHBiilhqWQiMFxp4TQxUqsDCg4RkKcKWKn5woQdNtiKmhBQWIiedgpgQo5q8vIDkIX8eIgIHHGCVTA0vuACnn2YaEsMIJJhXWKLGIXJCCCHk 2SkhNUgI4Kiopqrqqqy2akkgACH5BAkEAEgALAAAAAA8ADwAhpiYmJmZmZqampubm5ycnJ2dnZ+fn6CgoKGhoaKioqOjo6SkpKWlpaampqenp6ioqKmpqaqqqqurq6ysrK2tra6urq+vr7CwsLGxsbKysrOzs7S0tLW1tba2tre3t7i4uLm5ubq6uru7u7y8vL29vb6+vr+/v8DAwMHBwcLCwsPDw8TExMXFxcbGxsfHx8jIyMnJycrKysvLy8zMzM3Nzc7Ozs/Pz9DQ0NHR0dLS0tPT09TU1NXV1dbW1tfX19jY2NnZ2dra2tvb29zc3N3d3d7e3t/f3+Li4gAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf+gEiCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam4tHR5ygnp6gm6KfpI5FQ0NGh6aHIQoMHKiDQ0JCQ66ihwkAAAu1gre4RIavhQ4BAcDCSES4uK2EyIMiBcsDEs5IxLmF1YIMAM vB3EXRQsaD4RQDywQZ3ILQuLrsvIMIywAQ87bR1iGpBkHAsgKggvjwAeRQvW/4CC0gFyDCoQ8SIoCQ5IOHR4aGiN1DpCwAAkMcICAwYGACR48wf4QcmeiAAUMWEhzYacBipCA9YHrsIfPShQU7kzIQQclHUKE+LD1AkPSAAgqXhHQU2oNSg6oIJpTQBOQpj66THNg84EAeKCD+Cy1NmNDhn927ePMe+pEDx42/gHHkQGvpRAYLFRIrtnBBBaMcNSJLnowD04UGDRxo3ozZrSLIk0NXvmQB82bODTQwAoLDL+C/gglXIoEBseLEFiy40Mu7t29ON2jQsOTBgwlSNmS8WC6DkoY KFCpoGKFpx4zl2JtPer7YA4tLNGBgZ26Jg+3EGD5Q0hFj/AsYNTCFwHC7QgbHka5jh2+oRQtGIjBVSAgXKEZBXZHQgN0MNxjCAgoo7JbICBtssFEhJZgHnQeS5DDDDDkcAgOEKPwnSAwppBCDNRVucJwhKHjAQQqgqEDiC4OcAAIIJwySYYUI/vMCiSsQYkIIIbx9KAgILY41Dw0pQJiCdoKUgKSTgqDAAZBFctMCiRL6eGUhFFYooDAwRImCCg0SYmUIWAoCQwcVcqAkKl9CiCOGYxZCQotn4nkCCt8Z8macg4CggQaBklKDf23yCaeIIoxgIm9HJvmbIinsSOOmiNSQYnyg lmrqqaimqiopgQAAIfkECQQARwAsAAAAADwAPACGlpaWl5eXmJiYmZmZmpqam5ubnZ2dnp6en5+foKCgoaGhoqKio6OjpKSkpaWlpqamqKioqampqqqqq6urrKysra2trq6ur6+vsLCwsbGxsrKys7OztLS0tbW1tra2t7e3uLi4ubm5urq6u7u7vLy8vb29vr6+v7+/wMDAwsLCw8PDxMTExcXFxsbGx8fHyMjIycnJysrKy8vLzMzMzc3Nzs7Oz8/P0NDQ0dHR0tLS09PT1NTU1dXV1tbW19fX2NjY2dnZ2tra29vb3Nzc3d3d39/f4ODgAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAB/6AR4KDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbi0ZGnKBGRUWfoJqjo6aPQ0FBRIeoRYchCgwcqoNBPz9AsKiHCQAADLiCurtBhrGGDgEBAAvFR8e8r4TLhCEFzgMS0tO7P8nXv4QNAM7R30 LhP0LkqYMUA84EGN/G4b2D2IIIzgEg4BsEJNw7QaLiHYEgwFkBUD928PhxiB2yQQlLHWGALuChDxEggJDEI4fJHT4MFRSnqFmABIY4QEBgwIC3SCVN5tDRQ+U+RQcOGKqQIOgBAxEkAdGh0yRPTBYWGA3KQAQlHkyb7rD0AIFRAwooXAqSU+fWSQ6mIpBQQlOPHf5mKaU1cMBBBlM+ePCwNGFCh4GAAwsefKiHjRqIEyO2sfeSCQwU+kqeQMFCCkY2ZGjezNkGVAYMGogeDfoCoxucU8uogakC6NGkGdxd5EOxbRtnLZG4EHkyZQosCAsfTpxTjRgxLHHg0BYUDRcror+ghCG kBAxWM+WAwSK6dEoXIoiPIGHDiksyWnj/XimDhPERKPydhAP6+hYyMH2gAD+CZUkwrMdCfoWooAIjIIxUiAcTjAeBBpLEEB0LMHhWSAommBBcIiJkkMEHhpCggQQQQLCBJDfAUOEhLWRownmCvHDCCdMJAoKHGZBwyAkbaHACKCi42MIgJnjggQmDiIzo4S2AtZjhZUl+8IGOg3iAI5XfxHBChjQSQoKUWB5xggYebgClNCq4CGOUH4xQSAg4KliMC1uagIKFbLpJiAsbeKhBc7ikmeGGXkqpJyEdeiinKiuUYMKZhbb5EQYYLGrKDCuowFqIhh7iAgghrEnYl1MWp8gJRqJg aiIzoIACDavGKuustNZqqyqBAAAh+QQJBABDACwAAAAAPAA8AIaampqbm5ucnJydnZ2enp6fn5+hoaGioqKjo6OkpKSmpqanp6eoqKipqamqqqqrq6usrKytra2urq6vr6+wsLCxsbGysrKzs7O0tLS1tbW2tra3t7e4uLi5ubm6urq7u7u8vLy9vb2+vr7AwMDBwcHCwsLDw8PExMTFxcXGxsbHx8fIyMjJycnKysrLy8vMzMzNzc3Ozs7Pz8/Q0NDR0dHS0tLT09PU1NTV1dXW1tbX19fY2NjZ2dna2trb29vc3Nzd3d3e3t7f398AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAH/oBDgoOEhYaHiImKi4yNjo+QkZKTlJWWl5iZmpuLQUGcoEFAQJ+gmqKkpo89Ojo+h6ilqow6ODg5sKOys4q1tjuGsbyMPLa3P4XCw4u+OMCEysuJPcY4PNC60os7xriD0dqIOc bPQ+C8OjY23oXctjqDQp5CjxkLChqSNjP864bjzihZUCAAAIAF+vjxo3HjH7tIDwYEmAhAgSQdNBQubHgJQgEAEyca6EDpRkaNNSwlEBASAIEGl3bsQ0npQMgAAhiA0ISjhsKUkxAEAHlggqkc6iwxYHAhnNOnUKMKwgHjhdWrVmNwtARCwgMHYMM+iECCEQwWaNOqhYHpgYG3/nDjSmAUQ61dFi/axt1rwOiiHFWxXoVhA9OHCF/Dgn3w4ITUx5AjY6rLwtKFCx9MuUhhonMKShIYLGAggWQmGitOdPYMeunSBhZMXGKBYnVnFZYmNHDN4AEGSjJq20bRApOGB7wZRBghaYX tE8ULlSjBSEO+QhkcuF5QQRKLzidUsC00AgQI2Yk4TJiQwdAHCrsXWJAUQ8UKGYdQmAdBXdAKESLgJsgG602QmSEiWECBCKCIYF4IKAwCAgYY7CSIBxSsN184+pnH3CAeZJCBB4RgUCCJ0qwQwoOfgSgiioKEkOEEFXw4DAn7oefiiIWot951vKSwIggixFBIiDwSTZJCBetRcOAsOJqn444wDtJBgUCqUsIHINhICJJVDpKBBBJsMEwLJZAw3pEvHpKCBhtMCRWYkiUiAoUM1nmICwDmpeefgAYq6KCEXhIIACH5BAkEAEYALAAAAAA8ADwAhpeXl5iYmJmZmZubm5ycnJ6e np+fn6CgoKGhoaOjo6SkpKWlpaampqenp6ioqKmpqaqqqqurq6ysrK